本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 投资者可于 2023 年 11 月 22 日(星期三)至 11 月 28 日(星期二)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 （zqswb@gzlbp.com）进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 广州安必平医药科技股份有限公司（以下简称"公司"）已于 2023 年 10 月 31 日发布公司 2023 年第三季度报告，为便于广大投资者更全面深入地了解公 司 2023 年第三季度经营成果、财务状况，公司计划于 2023 年 11 月 29 日上午 9:00-10:00 举行 2023 年第三季度业绩说明会，就投资者关心的问题进行交 流。 一、 说明会类型 本次投资者说明会以网络互动召开，公司将针对 2023 年第三季度的经营成 果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 证券代码：688393 证券简称： ...

[Important Content Reminder](index=1&type=section&id=%E9%87%8D%E8%A6%81%E5%86%85%E5%AE%B9%E6%8F%90%E7%A4%BA) This section outlines the company's formal assurances regarding the accuracy and completeness of its quarterly report [Assurance of Truthfulness by Board, Supervisory Board, and Senior Management](index=1&type=section&id=%E8%91%A3%E4%BA%8B%E4%BC%9A%E3%80%81%E7%9B%91%E4%BA%8B%E4%BC%9A%E5%8F%8A%E9%AB%98%E7%AE%A1%E4%BF%9D%E8%AF%81%E7%9C%9F%E5%AE%9E%E6%80%A7) The board, supervisory board, senior management, and key financial officers collectively guarantee the truthfulness and completeness of the quarterly report and its financial statements - The company's board of directors, supervisory board, and senior management assume legal responsibility for the truthfulness, accuracy, and completeness of the quarterly report content[2](index=2&type=chunk) - The company's principal officer, officer in charge of accounting, and head of the accounting department guarantee the truthfulness, accuracy, and completeness of the financial information[3](index=3&type=chunk) [Key Financial Data](index=1&type=section&id=%E4%B8%80%E3%80%81%E4%B8%BB%E8%A6%81%E8%B4%A2%E5%8A%A1%E6%95%B0%E6%8D%AE) This section presents the company's key financial performance indicators, balance sheet metrics, and non-recurring items, along with explanations for significant changes [Key Accounting Data and Financial Indicators](index=1&type=section&id=%28%E4%B8%80%29%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) The company reported significant Q3 revenue and net profit growth, yet year-to-date cumulative figures declined, alongside a substantial decrease in operating cash flow and increased R&D investment Key Accounting Data and Financial Indicators | Item | Current Reporting Period (Q3 2023) | YoY Change (%) | Year-to-Date (YTD 2023) | YoY Change (%) | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 143,552,528.41 | - | 354,506,458.37 | -5.29 | | Net Profit Attributable to Shareholders of Listed Company | 19,489,757.01 | 130.95 | 37,594,415.51 | -13.86 | | Net Profit Attributable to Shareholders of Listed Company Excluding Non-Recurring Gains and Losses | 21,491,387.99 | 125.66 | 35,456,024.58 | -14.00 | | Net Cash Flow from Operating Activities | Not applicable | Not applicable | 3,210,037.42 | -80.50 | | Basic Earnings Per Share (RMB/share) | 0.21 | 133.33 | 0.40 | -14.89 | | Diluted Earnings Per Share (RMB/share) | 0.20 | 122.22 | 0.40 | -14.89 | | Weighted Average Return on Net Assets (%) | 1.56 | Increased by 0.87 percentage points | 3.02 | Decreased by 0.58 percentage points | | Total R&D Investment | 21,082,857.52 | 26.91 | 54,082,671.78 | 12.93 | | R&D Investment as % of Operating Revenue (%) | 14.69 | Increased by 2.09 percentage points | 15.26 | Increased by 2.47 percentage points | Key Balance Sheet Indicators | Indicator | End of Current Reporting Period (2023.09.30) | End of Prior Year (2022.12.31) | Change from Prior Year-End (%) | | :--- | :--- | :--- | :--- | | Total Assets | 1,381,770,194.59 | 1,392,783,829.88 | -0.79 | | Total Equity Attributable to Shareholders of Listed Company | 1,264,081,082.24 | 1,228,605,285.24 | 2.89 | [Non-Recurring Gains and Losses and Amounts](index=2&type=section&id=%28%E4%BA%8C%29%E9%9D%9E%E7%BB%8F%E5%B8%B8%E6%80%A7%E6%8D%9F%E7%9B%8A%E9%A1%B9%E7%9B%AE%E5%92%8C%E9%87%91%E9%A2%9D) The current period's total non-recurring gains and losses were negative due to net non-operating expenses, while year-to-date figures were positive, driven by government subsidies and entrusted investment income Non-Recurring Gains and Losses and Amounts | Item | Amount for Current Reporting Period (Q3 2023) | Amount Year-to-Date (YTD 2023) | | :--- | :--- | :--- | | Gains/Losses from Disposal of Non-Current Assets | 1,003.88 | -70,137.79 | | Government Subsidies Included in Current Profit/Loss | 220,368.28 | 2,815,782.56 | | Gains/Losses from Entrusted Investment or Asset Management | -149,576.43 | 3,492,706.98 | | Other Non-Operating Income and Expenses | -2,453,706.86 | -3,953,625.74 | | Other Profit/Loss Items Meeting the Definition of Non-Recurring Gains/Losses | - | 161,982.08 | | Less: Income Tax Impact | -389,345.00 | 205,298.39 | | Minority Interest Impact (After Tax) | 9,064.85 | 103,018.77 | | Total | -2,001,630.98 | 2,138,390.93 | [Changes in Key Accounting Data, Financial Indicators and Reasons](index=3&type=section&id=%28%E4%B8%89%29%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E3%80%81%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87%E5%8F%91%E7%94%9F%E5%8F%98%E5%8A%A8%E7%9A%84%E6%83%85%E5%86%B5%E3%80%81%E5%8E%9F%E5%9B%A0) Current period net profit and non-recurring net profit significantly increased due to higher revenue and lower expenses, while year-to-date operating cash flow declined sharply from reduced sales collections and increased employee compensation - Net profit attributable to shareholders and net profit attributable to shareholders excluding non-recurring gains and losses for the current period increased by **130.95%** and **125.66%** respectively, primarily due to increased revenue and reduced period expenses[9](index=9&type=chunk) - Net cash flow from operating activities decreased by **80.50%** year-to-date, mainly due to lower sales collections and increased employee compensation compared to the prior year[9](index=9&type=chunk) - Basic earnings per share increased by **133.33%** for the current period, primarily driven by increased profit[9](index=9&type=chunk) [Shareholder Information](index=3&type=section&id=%E4%BA%8C%E3%80%81%E8%82%A1%E4%B8%9C%E4%BF%A1%E6%81%AF) This section provides details on the total number of shareholders and the top ten shareholders' holdings, including information on controlling shareholders and related parties [Total Number of Common Shareholders, Preferred Shareholders with Restored Voting Rights, and Top Ten Shareholders' Holdings](index=3&type=section&id=%28%E4%B8%80%29%E6%99%AE%E9%80%9A%E8%82%A1%E8%82%A1%E4%B8%9C%E6%80%BB%E6%95%B0%E5%92%8C%E8%A1%A8%E5%86%B3%E6%9D%83%E6%81%A2%E5%A4%8D%E7%9A%84%E4%BC%98%E5%85%88%E8%82%A1%E8%82%A1%E4%B8%9C%E6%95%B0%E9%87%8F%E5%8F%8A%E5%89%8D%E5%8D%81%E5%90%8D%E8%82%A1%E4%B8%9C%E6%8C%81%E8%82%A1%E6%83%85%E5%86%B5%E8%A1%A8) As of the reporting period end, the company had **8,263** common shareholders, with high concentration among the top ten, including a significant combined stake held by controlling shareholder Cai Xiangting and his affiliates - The total number of common shareholders at the end of the reporting period was **8,263**[10](index=10&type=chunk) Top 10 Shareholders' Holdings | Shareholder Name | Shareholder Nature | Number of Shares Held (shares) | Shareholding Percentage (%) | | :--- | :--- | :--- | :--- | | Cai Xiangting | Domestic Natural Person | 19,817,000 | 21.18 | | Guangzhou Kaiduo Investment Consulting Center (Limited Partnership) | Other | 12,951,400 | 13.84 | | Zhuji Gaotejia Ruian Investment Partnership (Limited Partnership) | Other | 5,628,313 | 6.02 | | Xiamen Qianjing Enterprise Management Partnership (Limited Partnership) | Other | 5,358,418 | 5.73 | | Guangzhou Da'an Gene Technology Co., Ltd. | Domestic Non-State-Owned Legal Person | 3,486,000 | 3.73 | | Chongqing Gaotejia Ruian Equity Investment Fund Partnership (Limited Partnership) | Other | 2,407,600 | 2.57 | | Hangzhou Gaotejia Ruihai Investment Partnership (Limited Partnership) | Other | 1,480,679 | 1.58 | | Hangzhou Ruihong Investment Partnership (Limited Partnership) | Other | 722,467 | 0.77 | | Pan Weihua | Domestic Natural Person | 578,277 | 0.62 | | Feng Xiaodong | Domestic Natural Person | 513,888 | 0.55 | - Controlling shareholder Cai Xiangting is the executive partner of Guangzhou Kaiduo Investment Consulting Center (Limited Partnership), holding **69.64%** of its partnership interest[11](index=11&type=chunk) - Zhuji Gaotejia Ruian Investment Partnership, Chongqing Gaotejia Ruian Equity Investment Fund Partnership, Hangzhou Gaotejia Ruihai Investment Partnership, and Hangzhou Ruihong Investment Partnership are parties acting in concert[11](index=11&type=chunk) [Other Reminders](index=5&type=section&id=%E4%B8%89%E3%80%81%E5%85%B6%E4%BB%96%E6%8F%90%E9%86%92%E4%BA%8B%E9%A1%B9) This section addresses any other significant operational information requiring investor attention during the reporting period [Other Important Information Regarding the Company's Operating Performance During the Reporting Period Requiring Investor Attention](index=5&type=section&id=%E9%9C%80%E6%8F%90%E9%86%92%E6%8A%95%E8%B5%84%E8%80%85%E5%85%B3%E6%B3%A8%E7%9A%84%E5%85%B3%E4%BA%8E%E5%85%AC%E5%8F%B8%E6%8A%A5%E5%91%8A%E6%9C%9F%E7%BB%8F%E8%90%A5%E6%83%85%E5%86%B5%E7%9A%84%E5%85%B6%E4%BB%96%E9%87%8D%E8%A6%81%E4%BF%A1%E6%81%AF) The company has no other significant operating information requiring special investor attention during the reporting period - The company has no other important operating information requiring investor attention during the reporting period[12](index=12&type=chunk) [Quarterly Financial Statements](index=5&type=section&id=%E5%9B%9B%E3%80%81%E5%AD%A3%E5%BA%A6%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8) This section presents the company's unaudited consolidated financial statements, including the balance sheet, income statement, and cash flow statement [Type of Audit Opinion](index=5&type=section&id=%28%E4%B8%80%29%E5%AE%A1%E8%AE%A1%E6%84%8F%E8%A7%81%E7%B1%BB%E5%9E%8B) The financial statements for the current quarter are unaudited - The financial statements for the current quarter are unaudited[12](index=12&type=chunk) [Financial Statements](index=5&type=section&id=%28%E4%BA%8C%29%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8) This section presents the company's unaudited consolidated balance sheet, income statement, and cash flow statement as of September 30, 2023, and for the nine months then ended [Consolidated Balance Sheet](index=5&type=section&id=%E5%90%88%E5%B9%B6%E8%B5%84%E4%BA%A7%E8%B4%9F%E5%80%BA%E8%A1%A8) As of September 30, 2023, total assets slightly decreased, driven by lower current assets and higher non-current assets, while total liabilities decreased and owners' equity slightly grew Consolidated Balance Sheet Key Item Changes (2023.09.30 vs 2022.12.31) | Item | September 30, 2023 (RMB) | December 31, 2022 (RMB) | Change (%) | | :--- | :--- | :--- | :--- | | Cash and Cash Equivalents | 64,396,563.04 | 90,910,709.73 | -29.17 | | Financial Assets Held for Trading | 61,204,917.06 | 175,536,506.82 | -65.17 | | Accounts Receivable | 250,622,859.34 | 236,164,593.91 | 6.12 | | Inventories | 75,920,754.68 | 63,073,696.31 | 20.37 | | Non-Current Assets Due Within One Year | 72,853,774.43 | 0 | Newly Added | | Total Current Assets | 550,482,342.58 | 595,076,395.73 | -7.50 | | Other Non-Current Financial Assets | 173,238,842.50 | 147,449,916.08 | 17.49 | | Development Expenditures | 10,941,294.39 | 1,463,347.82 | 647.75 | | Total Non-Current Assets | 831,287,852.01 | 797,707,434.15 | 4.21 | | Total Assets | 1,381,770,194.59 | 1,392,783,829.88 | -0.79 | | Total Current Liabilities | 90,505,774.12 | 114,264,335.81 | -20.79 | | Total Liabilities | 142,721,204.12 | 170,447,006.45 | -16.38 | | Total Equity Attributable to Parent Company Shareholders | 1,264,081,082.24 | 1,228,605,285.24 | 2.89 | - Cash and cash equivalents and financial assets held for trading significantly decreased, while accounts receivable and inventories increased[13](index=13&type=chunk) - Development expenditures significantly increased, reflecting the company's increased investment in research and development[14](index=14&type=chunk) [Consolidated Income Statement](index=7&type=section&id=%E5%90%88%E5%B9%B6%E5%88%A9%E6%B6%A6%E8%A1%A8) For the first three quarters of 2023, total operating revenue, operating profit, and net profit all declined year-on-year, while sales and R&D expenses increased as a percentage of revenue Consolidated Income Statement Key Item Changes (Q1-Q3 2023 vs Q1-Q3 2022) | Item | Q1-Q3 2023 (Jan-Sep) (RMB) | Q1-Q3 2022 (Jan-Sep) (RMB) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Total Operating Revenue | 354,506,458.37 | 374,325,569.60 | -5.29 | | Operating Cost | 109,012,703.38 | 104,857,804.61 | 3.96 | | Selling Expenses | 125,589,751.86 | 132,682,257.48 | -5.35 | | Administrative Expenses | 58,819,729.69 | 53,795,656.72 | 9.34 | | R&D Expenses | 44,604,725.21 | 47,111,809.08 | -5.32 | | Operating Profit | 24,392,685.66 | 39,189,506.75 | -37.89 | | Total Profit | 20,439,059.92 | 38,591,651.76 | -47.03 | | Net Profit | 18,830,785.55 | 34,030,155.66 | -44.66 | | Net Profit Attributable to Parent Company Shareholders | 37,594,415.51 | 43,644,589.05 | -13.86 | | Basic Earnings Per Share (RMB/share) | 0.40 | 0.47 | -14.89 | - Total operating revenue decreased by **5.29%** year-on-year, leading to significant declines in operating profit, total profit, and net profit[19](index=19&type=chunk)[20](index=20&type=chunk) - Minority interest income/loss was negative and the loss expanded, impacting net profit attributable to parent company shareholders[20](index=20&type=chunk) [Consolidated Cash Flow Statement](index=10&type=section&id=%E5%90%88%E5%B9%B6%E7%8E%B0%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8) For Q1-Q3 2023, net operating cash flow significantly decreased, while net investing cash outflow narrowed, net financing cash outflow slightly increased, and period-end cash and cash equivalents declined year-on-year Consolidated Cash Flow Statement Key Item Changes (Q1-Q3 2023 vs Q1-Q3 2022) | Item | Q1-Q3 2023 (Jan-Sep) (RMB) | Q1-Q3 2022 (Jan-Sep) (RMB) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 3,210,037.42 | 16,462,893.85 | -80.50 | | Net Cash Flow from Investing Activities | -15,856,588.49 | -116,031,451.65 | 86.35 (Loss narrowed) | | Net Cash Flow from Financing Activities | -15,888,900.14 | -16,201,889.92 | 1.93 (Loss narrowed) | | Net Increase in Cash and Cash Equivalents | -28,614,146.69 | -115,580,870.56 | 75.25 (Loss narrowed) | | Cash and Cash Equivalents at Period End | 61,388,563.04 | 100,885,273.04 | -39.15 | - Decreased cash received from sales of goods and services, coupled with increased employee compensation, were the primary reasons for the significant decline in net cash flow from operating activities[23](index=23&type=chunk)[24](index=24&type=chunk) - Net cash outflow from investing activities significantly narrowed, mainly due to a substantial reduction in cash paid for the acquisition of fixed assets, intangible assets, and other long-term assets, as well as cash paid for investments[24](index=24&type=chunk) [Adjustments to Financial Statements at the Beginning of the First Year of Application of New Accounting Standards or Interpretations from 2023](index=12&type=section&id=2023%20%E5%B9%B4%E8%B5%B7%E9%A6%96%E6%AC%A1%E6%89%A7%E8%A1%8C%E6%96%B0%E4%BC%9A%E8%AE%A1%E5%87%86%E5%88%99%E6%88%96%E5%87%86%E5%88%99%E8%A7%A3%E9%87%8A%E7%AD%89%E6%B6%89%E5%8F%8A%E8%B0%83%E6%95%B4%E9%A6%96%E6%AC%A1%E6%89%A7%E8%A1%8C%E5%BD%93%E5%B9%B4%E5%B9%B4%E5%88%9D%E7%9A%84%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8) The company did not adopt new accounting standards or interpretations from 2023 that required adjustments to the financial statements at the beginning of the first year of application - The company did not adopt new accounting standards or interpretations from 2023 that required adjustments to the financial statements at the beginning of the first year of application[25](index=25&type=chunk)

证券代码：688393 证券简称：安必平 公告编号：2023-060 本公司监事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 广州安必平医药科技股份有限公司（以下简称"公司"）第三届监事会第二 十一次会议于 2023 年 10 月 30 日在公司会议室以现场结合通讯方式召开。本次 会议的通知于 2023 年 10 月 27 日以电子邮件、电话等通讯方式送达至公司全体 监事。本次会议由监事会主席彭振武先生召集并主持，会议应参与表决的监事 3 名,实际参与表决的监事 3 名。本次会议的召集、召开符合相关法律、法规、规 则及《公司章程》的有关规定。 二、监事会会议审议情况 经与会监事投票表决，审议通过了如下议案： （一）审议通过了《关于公司 2023 年第三季度报告的议案》 监事对 2023 年第三季度报告中关键指标等进行了审核，一致认为，公司 2023 年第三季度报告的编制符合法律、法规、规范性文件的规定，报告的内容真实、 准确、完整地反映了公司的实际情况。 表决结果：同意 3 票；反对 0 票；弃权 0 票。 ...

证券代码：688393 证券简称：安必平 公告编号：2023-061 广州安必平医药科技股份有限公司 关于为控股孙公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、担保情况概述 2023 年 10 月 30 日，公司召开第三届董事会第二十六次会议、第三届监事 会第二十一次会议，审议通过了《关于为控股孙公司提供担保的议案》，独立董 事对该事项发表了同意的独立意见。根据《上海证券交易所科创板股票上市规则》 和《公司章程》的有关规定，本次担保事项在董事会的决策范围内，经公司董事 会审议通过后生效，无需提交公司股东大会审议。 二、被担保人基本情况 被担保人的名称：浙江医辰生物科技有限公司 法定代表人：陶玲 经营范围：技术开发、技术咨询:生物技术;技术开发、技术服务、技术咨询、 成果转让:第 I、II、III 类医疗器械;销售:第 I、II、III 类医疗器械;安装、调 试:医疗设备;货物进出口（法律、行政法规禁止经营的项目除外,法律、行政法 规限制经营的项目取得许可后方可经营）。（依法须经批准 ...

一、《关于为控股孙公司提供担保的议案》 本次担保事项是为了满足控股孙公司正常经营的需要，有助于控股孙公司持 续发展，担保风险可控。本次担保事项的决策程序合法合规，符合相关法律法规 的要求，不会对公司本期及未来财务状况、经营成果产生不良影响，也不存在损 害公司及股东特别是中小股东利益的行为。 综上，独立董事同意公司为控股孙公司浙江医辰生物科技有限公司担保的事 项。 独立董事：宋小宁、吴翔、吴红日 广州安必平医药科技股份有限公司 独立董事关于第三届董事会第二十六次会议所审议相关事项的 独立意见 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司独立董 事规则》《上海证券交易所科创板股票上市规则》《广州安必平医药科技股份有限 公司章程》等有关规定，作为广州安必平医药科技股份有限公司（以下简称"公 司"）的独立董事，我们本着对公司及全体股东负责的态度，对公司第三届董事 会第二十六次会议所审议的相关事项，基于独立判断的立场发表意见如下： 2023 年 10 月 30 日 ...

证券简称：安必平 证券代码：688393 广州安必平医药科技股份有限公司 投资者关系活动记录表 编号：2023-013 □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系 活动类别 □新闻发布会 □√路演活动 □现场参观 □其他 万联证券谭剑波 中科沃土艾隆恺 盈拓私募沈磊 申万宏源曾巍 国金证 参与单位名称 券张颖 宽行基金蔡志权 陈怡 盛世纪朱钊伟 广州龙智投资钟锦松 中 旷投资罗旷 中信证券吴桂敏 禤贺珍 玄甲基金林佳义 李大志 时间 2023年10月25日 ...

证券简称：安必平 证券代码：688393 广州安必平医药科技股份有限公司 投资者关系活动记录表 编号：2023-012 □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系 活动类别 □新闻发布会 □√路演活动 □现场参观 □其他 长城基金沈文皓、新华基金张帅、荣疆投资陈舜义、长鸿资本唐国强、 参与单位名称 欣歌投资赵丽萍 时间 2023年10月18日 地点 民生证券策略会 公司接待人员 投资者关系高级经理：陈元元 ...

证券简称：安必平 证券代码：688393 广州安必平医药科技股份有限公司 投资者关系活动记录表 编号：2023-011 □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系 活动类别 □新闻发布会 □路演活动 □√现场参观 □其他 参与单位名称 兴证全球基金 谢长雁 时间 2023年10月10日 地点 公司会议室 董事会秘书：蔡幸伦 公司接待人员 投资者关系高级经理：陈元元 ...

证券代码：688393 证券简称：安必平 公告编号：2023-059 广州安必平医药科技股份有限公司 关于自愿披露公司及子公司 2023 年 7-9 月获得 资质情况的公告 | 序号 | 专利名称 | 专利号 | 授权公告日 | 专利类型 | | --- | --- | --- | --- | --- | | 1 | 分子杂交仪及其使用方法 | ZL201711015606.2 | 2023.7.14 | 发明专利 | | 2 | 大量图像拼接校正方法、 系统、装置、介质 | ZL202310339332.1 | 2023.7.14 | 发明专利 | | 3 | 样本瓶 | ZL202330218526.7 | 2023.9.5 | 外观设计 | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 广州安必平医药科技股份有限公司(以下简称"公司")及子公司在 2023 年 7-9 月获得国内医疗器械注册/备案证 16 项，获得知识产权类资质 6 项，获得 医疗器械质量管理体系认证 1 项。相关信息如下： 一、 获得资质的具体情 ...

证券简称:安必平 证券代码:688393 广州安必平医药科技股份有限公司 投资者关系活动记录表 编号:2023-010 □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系 活动类别 □新闻发布会 □路演活动 □√现场参观 □其他 参与单位名称 红塔红土基金、汇添富基金 时间 2023 年 9 月 22 日 地点 公司会议室 公司接待人员 投资者关系高级经理:陈元元 投资者关系活动 首先从公司业务板块、所属行业、研发以及经营情况、核心竞争 主要内容介绍 力、肿瘤检测技术平台及等市场拓展等方面对公司进行介绍,随后就投 资者关心的问题进行了沟通交流。 1. 公司的产品主要是针对哪些癌种? 答:首先在癌种上我们的液基细胞学和 HPV 筛查两个技术线比较 明确,妇科主要是以宫颈癌为主,非妇科会涉及到甲状腺癌、膀胱癌等 癌肿。其次,免疫组化(IHC),我们自产的抗体有 200 多种,荧光原 位杂交(FISH)探针的数量也有 100 多种,所以这两个产品线对应的 是很多不同癌种。比如说 HER2,它既可以做乳腺癌的诊断,也可以做 胃癌的诊断。所以有的技术平台看的是靶点,而不是看某一个癌种。综 合公司的技术平 ...